Advanced Filter

Filter by Group

Filter by Market Availability

Displaying all 4 drugs
Ebola virus (EBOV) remains an important human pathogen within the Ebolavirus genus, having been responsible for at least 17 known outbreaks with an average case fatality rate of 43.92%. Immune therapy using monoclonal antibodies (mAbs) is becoming an increasingly attractive therapeutic method to combat infectious diseases due to its rapid...
Approved
Matched Synonyms: … Maftivimab
Matched Name: … Maftivimab
Matched Description: … (REGN 3479), [Odesivimab] (REGN 3471), and [Atoltivimab] (REGN 3470) in equimolar proportions. ... [A222078] INMAZEB™, formerly referred to as REGN-EB3, combines the three humanized IgG1κ mAbs Maftivimab ... neutralizing and Fc-mediated immune effector function against EBOV _in vitro_ and protection against …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Ebola virus (EBOV) remains an important human pathogen within the Ebolavirus genus, having been responsible for at least 17 known outbreaks with an average case fatality rate of 43.92%. Immune therapy using monoclonal antibodies (mAbs) is becoming an increasingly attractive therapeutic method to combat infectious diseases due to its rapid...
Approved
Matched Synonyms: … Atoltivimab
Matched Name: … Atoltivimab
Matched Description: … (REGN 3470), [Odesivimab] (REGN 3471), and [Maftivimab] (REGN 3479) in equimolar proportions. ... [A222078] INMAZEB™, formerly referred to as REGN-EB3, combines the three humanized IgG1κ mAbs Atoltivimab ... neutralizing and Fc-mediated immune effector function against EBOV _in vitro_ and protection against …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Infection with pathogenic filoviruses, such as Zaire ebolavirus (Ebola virus, EBOV), can cause severe hemorrhagic fever in humans, resulting in frequent outbreaks with case fatality rates as high as 90%.[A225933, A225938] Virtually all steps of the EBOV lifecycle have been targeted for therapeutic development. However, to date, the most successful...
Approved
Investigational
Matched Description: … ], [odesivimab], and [maftivimab]), the now approved ansuvimab, and ZMapp, which remains in clinical ... sub> surface glycoprotein, as evidenced by the previously approved INMAZEB™ (REGN-EB3, a cocktail of [atoltivimab ... to be superior, with improved patient survival and faster viral clearance rates. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Immune Sera and Immunoglobulins …
Ebola virus (EBOV) remains an important human pathogen within the Ebolavirus genus, having been responsible for at least 17 known outbreaks with an average case fatality rate of 43.92%. Immune therapy using monoclonal antibodies (mAbs) is becoming an increasingly attractive therapeutic method to combat infectious diseases due to its rapid...
Approved
Matched Synonyms: … Odesivimab ... odesivimab-ebgn …
Matched Name: … Odesivimab
Matched Description: … (REGN 3471), [Maftivimab] (REGN 3479), and [Atoltivimab] (REGN 3470) in equimolar proportions. ... [A222078] INMAZEB™, formerly referred to as REGN-EB3, combines the three humanized IgG1κ mAbs Odesivimab ... neutralizing and Fc-mediated immune effector function against EBOV _in vitro_ and protection against …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Displaying all 4 drugs